Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors

2002 • 4,254 citations

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

2006 • 2,500 citations

PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

2003 • 2,224 citations

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

2003 • 2,216 citations

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

2003 • 1,939 citations

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

2004 • 1,629 citations

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

2003 • 1,236 citations

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

2003 • 1,172 citations

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

2006 • 862 citations

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

2003 • 860 citations

PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

2005 • 809 citations

Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation

2005 • 805 citations

Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

2006 • 793 citations

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

2001 • 698 citations

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

2003 • 634 citations

Combined inhibition of VEGF‐ and PDGF‐signaling enforces tumor vessel regression by interfering with pericyte‐mediated endothelial cell survival mechanisms

2003 • 598 citations

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

2005 • 556 citations

Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants

2005 • 491 citations

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

2004 • 439 citations

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

2003 • 380 citations

Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate

2006 • 355 citations

Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor

2007 • 338 citations

A Missense Mutation in KIT Kinase Domain 1 Correlates with Imatinib Resistance in Gastrointestinal Stromal Tumors

2004 • 338 citations

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

2004 • 324 citations

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

2003 • 305 citations

An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases

2006 • 284 citations

Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study

2005 • 280 citations

Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate

2006 • 274 citations

Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations

2005 • 188 citations

Switching on kinases: oncogenic activation of BRAF and the PDGFR family

2004 • 180 citations

Sorafenib Inhibits the Imatinib-Resistant KIT T670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

2007 • 142 citations

Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST)

2005 • 111 citations

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

2006 • 110 citations

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

2004 • 93 citations

Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status

2006 • 84 citations

Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala

2005 • 74 citations

Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour

2005 • 39 citations

Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour

2006 • 23 citations

Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines

2005 • 15 citations

Randomized trial of adjuvant equitoxic dose-escalated anthracycline (A)-containing regimen of doxorubicin, cyclophosphamide (AC) versus cyclophosphamide, methotrexate, 5-FU (CMF) for stage I-II breast cancer (BrCa): Can equitoxicity compensate for agent selection?

2005 • 10 citations

Synthesis and Antimelanoma Activity of Reversed Amide Analogues of N-Acetyl-4-S-cysteaminylphenol

2006 • 9 citations